Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date |
Reported DateTime |
Company | Symbol | Insider Relationship |
Shares Traded |
Average Price |
Total Amount |
Shares Owned |
Filing |
| 2025-03-14 Sale |
2025-03-18 5:30 pm |
Allogene Therapeutics Inc. | ALLO | Chang David D President and CEO |
46,668 | $1.96 | $91,469 | 8,189,765 (Indirect Direct) |
View |
| 2025-03-14 Sale |
2025-03-18 5:28 pm |
Allogene Therapeutics Inc. | ALLO | Beneski Benjamin Machinas SVP, Chief Technical Officer |
5,488 | $1.975 | $10,839 | 218,507 (Direct) |
View |
| 2025-02-18 Sale |
2025-02-20 4:15 pm |
Allogene Therapeutics Inc. | ALLO | MESSEMER DEBORAH M. Director |
13,313 | $2.43 | $32,351 | 144,316 (Direct) |
View |
| 2025-02-03 Sale |
2025-02-05 4:16 pm |
Allogene Therapeutics Inc. | ALLO | Douglas Earl Martin SVP, General Counsel |
6,404 | $1.71 | $10,951 | 587,848 (Direct) |
View |
| 2025-02-03 Sale |
2025-02-05 4:15 pm |
Allogene Therapeutics Inc. | ALLO | Parker Geoffrey M. CHIEF FINANCIAL OFFICER |
4,361 | $1.73 | $7,545 | 1,301,540 (Direct) |
View |
| 2025-02-03 Sale |
2025-02-05 4:14 pm |
Allogene Therapeutics Inc. | ALLO | MOORE TIMOTHY L. Chief Technical Officer |
14,746 | $1.71 | $25,216 | 250,713 (Direct) |
View |
| 2025-02-03 Sale |
2025-02-05 4:13 pm |
Allogene Therapeutics Inc. | ALLO | Chang David D President and CEO |
46,003 | $1.68 | $77,285 | 8,230,433 (Indirect Direct) |
View |
| 2025-02-03 Sale |
2025-02-05 4:12 pm |
Allogene Therapeutics Inc. | ALLO | Roberts Zachary EVP of R&D |
18,832 | $1.7 | $32,014 | 643,135 (Direct) |
View |
| 2025-01-21 Sale |
2025-01-23 4:30 pm |
Allogene Therapeutics Inc. | ALLO | Roberts Zachary EVP of R&D |
27,199 | $1.78 | $48,414 | 488,054 (Direct) |
View |
| 2024-12-09 Sale |
2024-12-10 4:53 pm |
Allogene Therapeutics Inc. | ALLO | MESSEMER DEBORAH M. Director |
9,136 | $2.18 | $19,916 | 157,629 (Direct) |
View |
| 2024-12-05 Sale |
2024-12-09 4:05 pm |
Allogene Therapeutics Inc. | ALLO | Humer Franz B Director |
9,221 | $2.16 | $19,917 | 307,507 (Direct) |
View |
| 2024-06-18 Sale |
2024-06-20 4:31 pm |
Allogene Therapeutics Inc. | ALLO | MESSEMER DEBORAH M. Director |
18,641 | $2.2793 | $42,488 | 166,765 (Direct) |
View |
| 2024-05-30 Sale |
2024-06-03 4:09 pm |
Allogene Therapeutics Inc. | ALLO | Humer Franz B Director |
11,200 | $2.3376 | $26,181 | 255,253 (Direct) |
View |
| 2024-05-16 Purchase |
2024-05-20 9:33 pm |
Allogene Therapeutics Inc. | ALLO | Belldegrun Arie Director |
1,724,137 | $2.9 | $4,999,997 | 10,099,279 (Indirect Direct) |
View |
| 2024-01-30 Purchase |
2024-03-06 9:52 pm |
Allogene Therapeutics Inc. | ALLO | Parker Geoffrey M. CHIEF FINANCIAL OFFICER |
190 | $3.595 | $683 | 819,590 (Direct) |
View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date |
Reported DateTime |
Exercisable Expiration |
Company | Symnbol | Insider Relationship |
Shares Traded |
Conversion Price |
Shares Owned |
Filing |
| 2025-03-01 Option Award |
2025-03-05 4:11 pm |
N/A 2035-03-01 |
Allogene Therapeutics Inc. | ALLO | Beneski Benjamin Machinas SVP, Chief Technical Officer |
144,094 | $0 | 336,334 (Direct) |
View |
Ownership |
2025-03-04 9:58 pm |
N/A N/A |
Allogene Therapeutics Inc. | ALLO | Beneski Benjamin Machinas SVP, Chief Technical Officer |
0 | $0 | 323,694 (Direct) |
View |
| 2025-01-24 Option Award |
2025-01-28 8:16 pm |
N/A 2035-01-24 |
Allogene Therapeutics Inc. | ALLO | Douglas Earl Martin SVP, General Counsel |
657,298 | $0 | 1,106,622 (Direct) |
View |
| 2025-01-24 Option Award |
2025-01-28 8:15 pm |
N/A 2035-01-24 |
Allogene Therapeutics Inc. | ALLO | Parker Geoffrey M. CHIEF FINANCIAL OFFICER |
788,757 | $0 | 1,920,745 (Direct) |
View |
| 2025-01-24 Option Award |
2025-01-28 8:14 pm |
N/A 2035-01-24 |
Allogene Therapeutics Inc. | ALLO | Yoshiyama Annie SVP, Finance |
164,325 | $0 | 266,083 (Direct) |
View |
| 2025-01-24 Option Award |
2025-01-28 8:13 pm |
N/A 2035-01-24 |
Allogene Therapeutics Inc. | ALLO | Roberts Zachary EVP of R&D |
788,757 | $0 | 1,276,811 (Direct) |
View |
| 2025-01-24 Option Award |
2025-01-28 8:11 pm |
N/A 2035-01-24 |
Allogene Therapeutics Inc. | ALLO | Belldegrun Arie Director |
1,677,884 | $0 | 12,317,030 (Direct) |
View |
| 2025-01-24 Option Award |
2025-01-28 8:10 pm |
N/A 2035-01-24 |
Allogene Therapeutics Inc. | ALLO | Chang David D President and CEO |
2,504,304 | $0 | 10,228,566 (Direct) |
View |
| 2024-10-21 Tax Withholding |
2024-10-23 4:21 pm |
N/A N/A |
Allogene Therapeutics Inc. | ALLO | Parker Geoffrey M. CHIEF FINANCIAL OFFICER |
36,404 | $2.84 | 1,131,988 (Direct) |
View |
| 2024-08-21 Tax Withholding |
2024-08-23 4:15 pm |
N/A N/A |
Allogene Therapeutics Inc. | ALLO | Douglas Earl Martin SVP, General Counsel |
28,310 | $2.785 | 449,324 (Direct) |
View |
Ownership |
2024-06-11 4:10 pm |
N/A N/A |
Allogene Therapeutics Inc. | ALLO | Yoshiyama Annie SVP, Finance |
0 | $0 | 450,466 (Direct) |
View |
| 2024-06-05 Option Award |
2024-06-07 5:35 pm |
N/A 2034-06-05 |
Allogene Therapeutics Inc. | ALLO | Mayo Stephen Director |
191,082 | $0 | 191,082 (Direct) |
View |
| 2024-06-05 Option Award |
2024-06-07 5:34 pm |
N/A 2034-06-05 |
Allogene Therapeutics Inc. | ALLO | Barrett Elizabeth A. Director |
191,082 | $0 | 191,082 (Direct) |
View |
| 2024-06-05 Option Award |
2024-06-07 5:33 pm |
N/A 2034-06-05 |
Allogene Therapeutics Inc. | ALLO | SATO VICKI L Director |
157,016 | $0 | 258,116 (Direct) |
View |
| 2024-06-05 Option Award |
2024-06-07 5:30 pm |
N/A 2034-06-05 |
Allogene Therapeutics Inc. | ALLO | Humer Franz B Director |
157,016 | $0 | 412,269 (Direct) |
View |
| 2024-06-05 Option Award |
2024-06-07 5:29 pm |
N/A 2034-06-05 |
Allogene Therapeutics Inc. | ALLO | WITTE OWEN N. Director |
191,082 | $0 | 191,082 (Direct) |
View |
| 2024-06-05 Option Award |
2024-06-07 5:28 pm |
N/A 2034-06-05 |
Allogene Therapeutics Inc. | ALLO | Kazam Joshua A Director |
191,082 | $0 | 191,082 (Direct) |
View |
| 2024-06-05 Option Award |
2024-06-07 5:25 pm |
N/A N/A |
Allogene Therapeutics Inc. | ALLO | MESSEMER DEBORAH M. Director |
122,950 | $0 | 185,406 (Direct) |
View |
| 2024-05-16 Option Award |
2024-05-20 9:33 pm |
N/A N/A |
Allogene Therapeutics Inc. | ALLO | Belldegrun Arie Director |
344,828 | $2.9 | 10,099,279 (Indirect) |
View |
| 2024-05-16 Option Award |
2024-05-20 6:02 pm |
N/A N/A |
Allogene Therapeutics Inc. | ALLO | Parker Geoffrey M. CHIEF FINANCIAL OFFICER |
344,828 | $2.9 | 1,164,418 (Direct) |
View |
| 2024-05-16 Option Award |
2024-05-20 6:01 pm |
N/A N/A |
Allogene Therapeutics Inc. | ALLO | Chang David D President and CEO |
344,828 | $2.9 | 7,723,302 (Direct) |
View |
| 2024-04-22 Tax Withholding |
2024-04-24 4:18 pm |
N/A N/A |
Allogene Therapeutics Inc. | ALLO | MOORE TIMOTHY L. Chief Technical Officer |
17,360 | $3.4671 | 265,459 (Direct) |
View |
| 2024-03-14 Tax Withholding |
2024-03-18 8:10 pm |
N/A N/A |
Allogene Therapeutics Inc. | ALLO | Chang David D President and CEO |
53,393 | $4.33 | 7,378,474 (Direct) |
View |
| 2024-01-25 Option Award |
2024-01-31 5:51 pm |
N/A 2034-01-25 |
Allogene Therapeutics Inc. | ALLO | MOORE TIMOTHY L. Chief Technical Officer |
438,115 | $0 | 624,334 (Direct) |
View |
| 2024-01-25 Option Award |
2024-01-31 5:48 pm |
N/A 2034-01-25 |
Allogene Therapeutics Inc. | ALLO | Douglas Earl Martin SVP, General Counsel |
189,578 | $0 | 625,412 (Direct) |
View |
| 2024-01-25 Option Award |
2024-01-31 5:47 pm |
N/A 2034-01-25 |
Allogene Therapeutics Inc. | ALLO | Parker Geoffrey M. CHIEF FINANCIAL OFFICER |
133,339 | $0 | 923,339 (Direct) |
View |